RARE
NASDAQ
US
Ultragenyx Pharmaceutical Inc. - Common Stock
$22.45
▲ +$1.03
(+4.81%)
Vol 1.8M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.2B
ROE
-414.2%
Margin
-92.0%
D/E
8352.12
Beta
0.10
52W
$26–$47
Wall Street Consensus
26 analysts · Apr 20268
Strong Buy
15
Buy
3
Hold
0
Sell
0
Strong Sell
88.5%
Buy Rating
Price Chart
Similar Stocks
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.11 | $-1.29 | $-0.18 |
| Sep 2025 | $-1.26 | $-1.81 | $-0.55 |
| Jun 2025 | $-1.32 | $-1.17 | +$0.15 |
| Mar 2025 | $-1.65 | $-1.57 | +$0.08 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -237.5% | -237.5% | -237.5% | -237.5% | -414.2% | -414.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -69.0% | -87.3% | -87.3% | -87.3% | -92.0% | -92.0% |
| Gross Margin | 86.2% | 85.3% | 85.3% | 85.3% | 84.7% | 84.7% |
| D/E Ratio | 559.61 | 0.00 | 559.61 | 559.61 | 8352.12 | 8352.12 |
| Current Ratio | 2.45 | 2.45 | 2.45 | 2.45 | 1.89 | 1.89 |
Key Ratios
ROA (TTM)
-43.7%
P/S (TTM)
3.52
P/B
15.2
EPS (TTM)
$-5.94
CF/Share
$-8.66
Rev Growth 3Y
+16.8%
52W High
$46.50
52W Low
$25.81
$25.81
52-Week Range
$46.50
How does RARE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RARE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.5
▼
73%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
15.2
▲
519%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RARE profitability vs Biotechnology peers
ROE
-414.2%
▼
515%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-92.0%
▲
68%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
84.7%
▲
8%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-43.7%
▲
7%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
RARE financial health vs Biotechnology peers
D/E ratio
8352.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.9
▼
57%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.1
▼
89%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
RARE fundamentals radar
RARE
Peer median
Industry
RARE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
RARE vs peers: key metrics
Latest News
Xanadu: Rare Public Debut March 27 of Full-Stack Photonic Quantum Company – …
Yahoo Finance · Mar 25
USA Rare Earth (USAR) Loses 8.82% as Lawmaker Questions Lutnick Conflict of …
Yahoo Finance · Mar 22
USA Rare Earth vs. MP Materials: Which Mining Stock Should You Buy …
Yahoo Finance · Mar 21
How CNBC Cures is bringing rare disease stories to a national audience
CNBC · Mar 21
The Three Companies Rebuilding America’s Rare-Earth Arsenal
Yahoo Finance · Mar 21